Search
AstraZeneca's Alexion Pharmaceuticals has inked a global, exclusive licensing agreement with Japanese pharmaceutical giant JCR Pharma. The agreement grants Alexion access to JCR Pharma's innovative JUST-AAV capsid platform for the development of advanced gene therapies. Under the terms of the deal, Alexion can utilize this technology across up to five projects, with an initial payment and potential milestone payments totaling $825 million, in addition to royalties on sales. This marks the third collaboration between the two companies since 2020, following successful ventures involving J-Brain Cargo® technology for neurodegenerative disease treatment and oligonucleotide therapies. Notably, the first drug leveraging J-Brain Cargo® technology has already received approval in Japan for the treatment of lysosomal storage disorders.
-
C114 Communication Network -
Communication Home
